Efficacy of celecoxib for pain relief and antipyresis in pregnant women receiving misoprostol for termination of pregnancy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160109001

Enrollment

Registered

2016-01-09

Start date

2015-12-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Women with intrauterine pregnancy requesting therapeutic abortion for any indications

Interventions

Celecoxib (celebrex) 400 mg 1 capsule oral just before first dose of misoprostol,Placebo (white green capsule as same as celebrex) 1 capsule oral just before first dose of misoprostol

Active Comparator Drug,Placebo Comparator Drug

Celecoxib ,Placebo

Eligibility

Sex/Gender

Female

Age

No minimum to 0 Years

Inclusion criteria

Inclusion criteria: Women with intrauterine pregnancy requesting therapeutic abortion for any indications and Gestational age 14-24 weeks which is confirmed by USG

Exclusion criteria

Exclusion criteria: - Allergy to NSAIDs/Sulfa - Contraindicate for Celecoxib - History of fever, PROM, vaginal bleeding, abdominal pain - History of previous induced abortion by medication or devices

Design outcomes

Primary

Measure	Time frame
Pain score every hour after taking first dose misoprostol in intervention and control group within 24 hours after taking first dose misoprostol VAS	—

Secondary

Measure	Time frame
Body temperature every hour after taking first dose misoprostol in intervention and control group within 24 hours after taking first dose misoprostol Infarated Thermometer	—

Countries

Thailand

Contacts

Public ContactPeangpailin Voradithi

Songkhlanakarind hospital

p.voradith@gmail.com66891642444

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026